BIOS Health develops an AI-driven brain data and neural digital therapy platform that identifies neural biomarkers to connect nerve activity with specific illnesses. The company focuses on leveraging nervous-system data to create neural digital therapies and accelerate precision medicine for conditions such as hypertension, diabetes, rheumatoid arthritis, Parkinson’s and Alzheimer’s. BIOS positions its technology as a way to codify the "neural code" and enable a new generation of medicines and data-driven clinical trials. The firm says it will use the new funds and revenue growth to build market share. BIOS was founded in 2015 by Cambridge University researchers Emil Hewage and Oliver Armitage and its team spans neuroscience, machine learning, software, applied biomaterials, biotech and medicine. Earlier this year the NIH and institutions including the University of Minnesota, the Mayo Clinic, and Stanford chose BIOS’ technology to power the three-year, eight-clinic REVEAL programme, described by BIOS as the largest clinical investigation of human brain data to date. BIOS Health is developing an AI-controlled closed-loop neuromodulation system aimed at treating chronic cardiac conditions by linking neural and cardiac signals. The company collaborates with academic partners including Mila, McGill University and Université de Montréal, and works closely with researchers Dr. Blake Richards and Dr. Guillaume Lajoie. Its work focuses on using machine learning to decode neural‑to‑cardiac relationships and identify neural biomarkers that enable personalized, second-by-second modulation of cardiac function. The technology aims to preferentially modulate cardiac activity while reducing side effects on other organs, potentially replacing some pharmaceutical interventions. BIOS plans to advance the program toward human clinical trials, with the CEO stating the next stage will take the project up to the point of clinical testing. The company’s research programme began with a CA$800,000 partnership launched in 2020 and is being expanded through new, project-specific funding. BIOS is developing a core neural interface product and related AI that the company says can connect to organs and nerve systems across the body. Its first product, described as a “USB connector for the body,” enabled a Prosthetic Interface Device (PID) that lets amputees connect prostheses directly to the nervous system and is about to enter clinical trials. R&D has produced safer, more accurate hardware and yielded a large neural data set that BIOS uses to train its algorithms. The company plans to both build some products itself and partner with commercial and academic organisations, expanding access via tools, data sets and algorithms for discovering neural biomarkers. BIOS is originally based in Cambridge, U.K., and has opened an additional R&D office in Montreal, Canada. The startup will use the funding to double its technical team and further develop its core neural-interface technologies while helping push industry standards and formats for neural data.

Total raised

$6M

Funding rounds

3

Latest round

Equity

Latest activity

Jul 2022